Inferior vena cava filter
| Inferior vena cava filter | |
 | |
|---|---|
| Inferior vena cava filter (Gunther Tulip) [1] |
Editor in Chief: Mohammad Arabi, M.D, FRCR [1]Associate Editor-In-Chief : Muhammad Saad, M.B.B.S.[2] Gonzalo A. Romero, M.D. [3], Marcelo R. Zacarkim, M.D. [4]
Overview
An inferior vena cava filter (IVC filter) is a medical device that is implanted into the inferior vena cava to mechanically intercept venous thrombi and prevent pulmonary emboli (PE).[2] IVC filters exist in both permanent and retrievable (optional) forms. They are primarily indicated when anticoagulation is contraindicated, has failed, or has resulted in complications in patients with venous thromboembolism (VTE).[3]
A systematic review and meta-analysis demonstrated that IVC filters reduce the risk of subsequent PE by approximately 50% but increase the risk of deep vein thrombosis (DVT) by approximately 70%, with no significant effect on all-cause mortality.[4] In the United States, IVC filter insertions have declined substantially, from 44,680 per year in 2013 to 19,501 per year in 2021, reflecting increased alignment between guidelines and clinical practice following FDA safety communications and updated societal recommendations.[5]
The 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline recommends that retrievable IVC filters are preferred over permanent filters in patients with acute PE who cannot receive anticoagulation (Class 1, Level of Evidence B-R), and that routine IVC filter placement in therapeutically anticoagulated patients should not be performed (Class 3: Harm).[2]
Historical perspective
Caval interruption to prevent pulmonary embolism was first performed surgically by Trendelenburg in the early 1900s.[3] Surgical ligation and plication of the inferior vena cava were used through the mid-20th century. The first intracaval filter device, the Mobin-Uddin umbrella filter, was introduced in the 1960s. In 1973, Greenfield and colleagues developed a new intracaval filter permitting continued flow and resolution of emboli, which became the standard for decades.[6] Percutaneous insertion techniques were developed in the 1980s, and retrievable filter designs became available in the late 1990s, fundamentally changing clinical practice.[3] After an FDA safety communication in 2010 regarding risks of long-term indwelling filters, annual IVC filter use declined significantly in the United States.[7]
Classification
IVC filters are classified into three general categories:
Permanent filters
Permanent filters are designed for lifelong implantation and are not intended for removal. They are reserved for rare cases in which retrievable IVC filters are not feasible, such as patients with a mega cava (IVC diameter >30 mm).[2] Examples include:
Stainless steel Greenfield filter
Bird's Nest filter (Cook Medical) — approved for cavas larger than 28 mm
VenaTech LGM and LP filters (B. Braun)
TrapEase filter (Cordis)
Simon Nitinol filter
Retrievable (optional) filters
Retrievable filters are designed to be either removed when no longer needed or left in place as permanent devices. They are the preferred type in current practice.[2] Examples include:
Günther Tulip filter (Cook Medical)
Celect filter (Cook Medical)
OptEase filter (Cordis)
G2 / G2 Express filter (Bard)
ALN filter (Pyramed)
Denali filter (Bard)
Option filter (Rex Medical)
Convertible filters
Convertible filters can be structurally modified in situ to allow blood flow through the device while leaving the filter frame in place, effectively converting from a filtering to a non-filtering state.
Indications for use
2026 AHA/ACC Guideline Recommendations
The 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline provides the following recommendations for IVC filter use:[2]
| Class of Recommendation | Level of Evidence | Recommendation |
|---|---|---|
| Class 1 | B-R | In patients with acute PE who cannot tolerate anticoagulation but in whom an IVC filter is deemed necessary, retrievable IVC filters are recommended over permanent filters to reduce the short-term incidence of recurrent PE while minimizing long-term adverse outcomes. |
| Class 1 | C-LD | In patients with retrievable IVC filters, retrieval should be attempted as soon as the risk of PE has sufficiently decreased and anticoagulation can be tolerated, to minimize the risk of long-term filter-related complications. |
| Class 2a | B-R | In patients with acute PE who cannot tolerate anticoagulation, IVC filters can be useful to reduce the short-term incidence of recurrent PE. |
| Class 2a | C-LD | In patients with indwelling IVC filters, the use of a structured follow-up program is reasonable to increase retrieval rates and detect complications. |
| Class 2b | C-LD | In patients with acute PE in AHA/ACC PE Categories D-E undergoing advanced interventions (systemic thrombolysis, catheter-directed lysis, mechanical thrombectomy, or surgical embolectomy), the benefit of IVC filter placement is uncertain. |
| Class 2b | C-LD | In patients with recurrent PE despite optimal therapeutic anticoagulation (AHA/ACC PE Categories B-E), IVC filter placement may be considered. |
| Class 3: Harm | A | In patients with acute PE who are therapeutically anticoagulated, routine IVC filter placement should not be performed. |
Traditional indications
Most filters are placed under one of the following clinical scenarios:
Accepted indications (in the presence of deep vein thrombosis and/or pulmonary embolism):
Absolute contraindication to anticoagulation (e.g., active hemorrhage, recent intracranial hemorrhage, major trauma)
Complication of anticoagulation (e.g., heparin-induced thrombocytopenia, major bleeding)
Recurrent pulmonary embolism or progression of DVT despite adequate anticoagulation
Relative indications (in the presence of DVT/PE):
Large free-floating thrombus in the IVC or iliofemoral veins
Patients with limited cardiopulmonary reserve in whom a subsequent PE would likely be fatal
Non-compliant patients unable to maintain therapeutic anticoagulation
Prophylactic indications (in the absence of documented DVT/PE) — use is controversial and not supported by current guidelines:
Major trauma with contraindication to pharmacologic thromboprophylaxis
High-risk surgical patients unable to receive anticoagulation
Placement
Technique
IVC filters are placed endovascularly via percutaneous access to the venous system. Common access sites include:
Femoral vein (most common approach)
Internal jugular vein (preferred when femoral access is contraindicated or when extensive iliofemoral vein thrombosis is present)
Arm veins (antecubital approach, available with select filter designs)
The choice of access route depends primarily on the location and extent of venous thrombosis.
Procedure
A catheter is advanced into the IVC through the venous access site using fluoroscopic guidance.
A venogram is performed using iodinated contrast material or carbon dioxide to define the anatomy and caliber of the IVC and to determine the level of the lowest renal vein.
The filter is introduced through an introducer sheath and deployed into the desired location, typically just below the junction of the IVC and the lowest renal vein.
Alternatively, bedside deployment can be performed using intravascular ultrasound (IVUS) guidance, particularly in critically ill patients in the intensive care unit.
Pre-procedural considerations
Review of prior cross-sectional imaging (e.g., CT) or a venogram of the IVC is essential before deployment to assess for:
Anatomic variations (e.g., IVC duplication, left-sided inferior vena cava)
Thrombi within the IVC
Areas of stenosis
IVC diameter (affects filter selection; some filters such as the Bird's Nest are approved for cavas >28 mm)
Special anatomic situations
Suprarenal placement may be indicated in pregnant patients or women of childbearing age, renal vein thrombosis, or gonadal vein thrombosis
Duplicated IVC: A filter may be placed above the confluence of the two IVCs, or a filter can be placed within each IVC
Mega cava (IVC >30 mm): Permanent filters (e.g., Bird's Nest) may be required, as most retrievable filters are not designed for this diameter[2]
Complications
Periprocedural complications
Puncture site hematoma or venous thrombosis
Incorrect deployment requiring retrieval:
Malpositioning
Incorrect sizing with subsequent filter embolization
Filter tilt
Failure to open completely
Pneumothorax (with jugular access)
Delayed complications
Device-related complications of indwelling IVC filters include:[7][2]
IVC thrombosis — caval thrombosis occurred in 2.2% and DVT requiring hospitalization in 9.2% of patients with nonretrieved filters in the SAFE-IVC study[5]
Recurrent pulmonary embolism — despite filter placement
IVC perforation — strut penetration through the caval wall into adjacent structures
Filter migration — caudal (toward the iliac veins) or cranial (toward the heart)
Strut fracture — with potential embolization of fractured components
Strut embolization — to the heart or pulmonary arteries
Device tilt — may reduce filtering efficacy
Post-thrombotic syndrome — occurred in approximately 70% of patients in both filter and no-filter groups in the PREPIC trial at 8 years[8]
SAFE-IVC Study: Real-world complication rates
The SAFE-IVC study (2024), the largest postmarketing surveillance study of IVC filters, evaluated 270,866 Medicare beneficiaries who received IVC filters between 2013 and 2021:[5]
| Outcome | Incidence |
|---|---|
| Periprocedural (≤30 days of insertion) composite | 27.3% |
| All-cause death (≤30 days of insertion) | 14.6% |
| Operating room visits post-insertion | 9.6% |
| Filter-related complications (insertion) | <1% |
| Long-term indwelling filter outcomes | |
| DVT requiring hospitalization | 9.2% (95% CI, 9.0%-9.3%) |
| Caval thrombosis | 2.2% (95% CI, 2.1%-2.3%) |
| Filter-related complications | 1.4% |
| Periprocedural (≤30 days of retrieval) composite | 3.9% |
| Mortality post-retrieval | 0.7% (95% CI, 0.6%-0.8%) |
| Filter-related complications (retrieval) | 0.7% |
The high 30-day mortality after insertion (14.6%) was attributed to the underlying conditions (major bleeding, trauma) that prompted filter placement rather than to the filter itself.[5]
Classification of complications by outcome
The Society of Interventional Radiology (SIR) Standards of Practice Committee classifies complications as follows:
Minor complications:
No therapy, no consequence
Nominal therapy, no consequence; includes overnight admission for observation only
Major complications:
Require therapy, minor hospitalization (<48 hours)
Require major therapy, unplanned increase in level of care, prolonged hospitalization (>48 hours)
Permanent adverse sequelae
Death
Retrieval
Rationale for timely retrieval
Timely retrieval of retrievable IVC filters is essential to minimize long-term risks. The U.S. Food and Drug Administration (FDA) issued a safety communication recommending IVC filter retrieval within 29 to 54 days after placement, once the risk of PE has subsided.[2] Filter retrieval becomes progressively more difficult with increasing dwell time:
Challenging retrievals are more common after 50 days
Failed retrievals are more frequent after 90 days of dwell time
Successful retrievals had a mean dwell time of 85 days, while unsuccessful retrievals averaged 145 days
Delayed retrieval may require advanced techniques such as large-bore sheaths, longer procedural times, or general anesthesia
Longer dwell times are associated with filter embedment and IVC perforation[2]
Retrieval technique
Retrieval is most commonly performed via the internal jugular vein using a snare or retrieval cone device under fluoroscopic guidance. The retrieval hook at the cephalad end of the filter is engaged and the filter is collapsed into a retrieval sheath.
Retrieval rates
Despite recommendations for timely retrieval, national retrieval rates remain suboptimal:
In the SAFE-IVC study, the cumulative incidence of retrieval was only 15.3% at a median of 1.2 years and 16.8% at maximum follow-up of 9.0 years[5]
93.5% of retrieval attempts were successful[5]
Older age, more comorbidities, and Black race were associated with decreased likelihood of retrieval, whereas placement at a large teaching hospital was associated with increased likelihood of retrieval[5]
In the PRESERVE study, filters were removed from 44.5% of patients at a mean of 101.5 days (median 86.3 days)[9]
Despite data demonstrating the safety and ease of retrieval, up to 50% of retrievable IVC filters remain permanently indwelling[7]
Structured follow-up programs
The 2026 AHA/ACC guideline recommends the use of structured follow-up programs to increase retrieval rates and detect complications (Class 2a, Level of Evidence C-LD).[2] Evidence-based strategies include:
Implementing a retrieval plan at the time of filter placement
Referral to specialty clinics with scheduled follow-up appointments
Automated reminder systems for patients and providers
Enhanced patient instructions at discharge
Institutional quality improvement programs
Multidisciplinary approaches involving standardized protocols and provider education
Algorithm for IVC filter management
The following algorithm summarizes the decision-making process for IVC filter placement and retrieval based on the 2026 AHA/ACC guideline:[2]
| Step 1: Patient with Acute PE or DVT | |
|---|---|
| ↓ | |
| Can the patient receive therapeutic anticoagulation? | |
| YES | NO |
| Do NOT place IVC filter (Class 3: Harm) Treat with anticoagulation alone |
Place RETRIEVABLE IVC filter (Class 1, LOE B-R) Preferred over permanent filter |
| ↓ (If filter placed) | |
| Step 2: Post-Filter Placement Management | |
| Establish structured follow-up program (Class 2a, LOE C-LD) Schedule retrieval assessment; implement reminder systems | |
| ↓ | |
| Can anticoagulation be initiated/resumed AND has PE risk decreased? | |
| YES | NO |
| Retrieve filter (Class 1, LOE C-LD) Ideally within 29–54 days (FDA recommendation) Challenging retrievals more common after 50 days Failed retrievals more frequent after 90 days |
Continue monitoring Reassess at regular intervals Monitor for filter-related complications (DVT, caval thrombosis, migration, fracture) |
| Special Considerations | |
|
Mega cava (>30 mm): Permanent filter may be required (retrievable filters not designed for this diameter) Recurrent PE despite anticoagulation: IVC filter may be considered (Class 2b, LOE C-LD) Advanced PE interventions (Categories D-E): Benefit of IVC filter is uncertain (Class 2b, LOE C-LD) Suprarenal placement: Consider in pregnancy, renal vein thrombosis, or gonadal vein thrombosis Duplicated IVC: Place filter above confluence or one filter in each IVC | |
Landmark trials
1. PREPIC Trial (1998) and 8-Year Follow-Up (2005)
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis[10]
Design: Randomized controlled trial using a two-by-two factorial design. 400 patients with proximal DVT at risk for PE were randomized to receive either an IVC filter (200 patients) or no filter (200 patients), and to receive enoxaparin (195 patients) or unfractionated heparin (205 patients).
Results at day 12: Symptomatic or asymptomatic PE occurred in 1.1% of the filter group vs. 4.8% of the no-filter group (OR 0.22; 95% CI, 0.05-0.90).
Results at 2 years: Recurrent DVT occurred in 20.8% of the filter group vs. 11.6% of the no-filter group (OR 1.87; 95% CI, 1.10-3.20). No significant differences in mortality or other outcomes.
Eight-Year Follow-Up (PREPIC Study)[8]
Results at 8 years: Symptomatic PE occurred in 6.2% of the filter group vs. 15.1% of the no-filter group (p=0.008). DVT occurred in 35.7% of the filter group vs. 27.5% of the no-filter group (p=0.042). Post-thrombotic syndrome occurred in approximately 70% of both groups. No survival difference: overall mortality was 50.3% (103 vs. 98 deaths).
Conclusion: IVC filters reduced the risk of PE but increased the risk of DVT, with no effect on survival.
2. PREPIC2 Trial (2015)
Effect of a Retrievable Inferior Vena Cava Filter Plus Anticoagulation vs Anticoagulation Alone on Risk of Recurrent Pulmonary Embolism[11]
Design: Randomized, open-label, blinded endpoint trial. 399 hospitalized patients with acute symptomatic PE associated with lower-limb DVT and at least 1 severity criterion were randomized to retrievable IVC filter plus anticoagulation (n=200) or anticoagulation alone (n=199). All patients received full-dose anticoagulation for at least 6 months. Filter retrieval was planned at 3 months.
Results: The filter was successfully inserted in 193 patients and retrieved as planned in 153 of 164 patients in whom retrieval was attempted. By 3 months, recurrent PE occurred in 6 patients (3.0%; all fatal) in the filter group vs. 3 patients (1.5%; 2 fatal) in the control group (relative risk 2.00; 95% CI, 0.51-7.89; p=0.50). Results were similar at 6 months. No difference was observed in DVT, major bleeding, or death. Filter thrombosis occurred in 3 patients.
Conclusion: Among hospitalized patients with severe acute PE, the use of a retrievable IVC filter plus anticoagulation compared with anticoagulation alone did not reduce the risk of symptomatic recurrent PE at 3 months. These findings do not support the use of retrievable IVC filters in patients who can be treated with anticoagulation.
3. Bikdeli et al. Meta-Analysis (2017)
Inferior Vena Cava Filters to Prevent Pulmonary Embolism: Systematic Review and Meta-Analysis[4]
Design: Systematic review and meta-analysis of 11 studies (2 randomized controlled trials and 9 prospective controlled observational studies).
Results: IVC filters were associated with:
Approximately 50% reduction in recurrent PE
Approximately 70% increase in DVT risk
No significant effect on all-cause mortality
A post hoc analysis of 3 studies with cohorts similar to guideline-recommended indications (contraindications to anticoagulation or recurrent VTE despite adequate anticoagulation) showed trends toward reduced risk of recurrent PE (OR 0.47; 95% CI, 0.21-1.04), increased risk of subsequent DVT (OR 7.21; 95% CI, 1.53-33.85), reduced PE-related mortality (OR 0.20; 95% CI, 0.06-0.64), and no change in all-cause mortality (OR 0.70; 95% CI, 0.42-1.16).
4. SAFE-IVC Study (2024)
Postmarketing Surveillance of Inferior Vena Cava Filters Among US Medicare Beneficiaries[5]
Design: Retrospective observational cohort of 270,866 Medicare Fee-for-Service beneficiaries with first-time IVC filter insertion from 2013 to 2021. Mean age 75.1 years; 52.8% female.
Key findings:
64.9% placed for first-time VTE, 26.3% for recurrent VTE, 8.8% for VTE prophylaxis
63.3% had major bleeds or trauma within 30 days of insertion
Insertions declined from 44,680/year (2013) to 19,501/year (2021)
Cumulative retrieval rate: 15.3% at median 1.2 years; 16.8% at maximum 9-year follow-up
93.5% of retrieval attempts were successful
Among nonretrieved filters: DVT requiring hospitalization 9.2%, caval thrombosis 2.2%, filter-related complications 1.4%
Conclusion: IVC filter insertion declined, yet retrievals remained low. Strategies to increase timely retrieval are needed, as nonretrieved IVC filters may have long-term complications.
5. PRESERVE Study (2023)
Predicting the Safety and Effectiveness of Inferior Vena Cava Filters[9]
Design: Prospective, nonrandomized, multicenter study of 1,429 participants at 54 US sites. 71.7% had current DVT and/or PE; 81.6% had contraindication or failure of anticoagulation.
Results: 96.4% freedom from symptomatic PE at 12 months. Filters were removed from 44.5% at mean 101.5 days (median 86.3 days). VCF-related adverse events were rare (0.5% excluding strut perforation). Post-filter VTE events occurred in 6.5% (DVT 5.2%, PE 1.6%, caval thrombotic occlusion 1.1%).
Conclusion: IVC filters demonstrated high procedural success and effectiveness when appropriately used in patients with guideline-recommended indications.
Diagnostic findings
Inferior vena cava filter thrombosis
IVC filter thrombosis can be detected on CT imaging as filling defects within or surrounding the filter device. Duplex ultrasonography may also be used for surveillance, though CT provides superior anatomic detail.
Video of IVC filter deployment
{{#ev:youtube|RLWwCfVk01k}}
References
- ↑ Gunther Tulip IVC Filter. Accessed on: November 24, 2007
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 Creager MA, Barnes GD, Giri J, et al. (2026). "2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults". J Am Coll Cardiol.
- ↑ 3.0 3.1 3.2 Kaufman JA, Barnes GD, Chaer RA, et al. (2020). "Society of Interventional Radiology Clinical Practice Guideline for Inferior Vena Cava Filters in the Treatment of Patients with Venous Thromboembolic Disease". J Vasc Interv Radiol. 31 (10): 1529–1544. doi:10.1016/j.jvir.2020.06.014. PMID 32919842 Check
|pmid=value (help). - ↑ 4.0 4.1 Bikdeli B, Chatterjee S, Desai NR, et al. (2017). "Inferior Vena Cava Filters to Prevent Pulmonary Embolism: Systematic Review and Meta-Analysis". J Am Coll Cardiol. 70 (13): 1587–1597. doi:10.1016/j.jacc.2017.07.775. PMID 28935036.
- ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 Ferro EG, Mackel JB, Kramer RD, et al. (2024). "Postmarketing Surveillance of Inferior Vena Cava Filters Among US Medicare Beneficiaries: The SAFE-IVC Study". JAMA. 333 (3): 232–243. doi:10.1001/jama.2024.23831. PMID 39504004 Check
|pmid=value (help). - ↑ Greenfield LJ, McCurdy JR, Brown PP, Elkins RC (1973). "A new intracaval filter permitting continued flow and resolution of emboli". Surgery. 73 (4): 599–606. PMID 4690119.
- ↑ 7.0 7.1 7.2 Piazza G (2020). "Advanced Management of Intermediate- and High-Risk Pulmonary Embolism: JACC Focus Seminar". J Am Coll Cardiol. 76 (18): 2117–2127. doi:10.1016/j.jacc.2020.05.028. PMID 33121723 Check
|pmid=value (help). - ↑ 8.0 8.1 PREPIC Study G (2005). "Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study". Circulation. 112 (3): 416–422. doi:10.1161/CIRCULATIONAHA.104.512834. PMID 16009794. Vancouver style error: initials (help)
- ↑ 9.0 9.1 Johnson MS, Defined MH, et al. (2023). "Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE): Outcomes of a Prospective, Multicenter Trial". J Vasc Interv Radiol. 34 (5): 802–811. PMID 36841633 Check
|pmid=value (help). - ↑ Decousus H, Leizorovicz A, Parent F, et al. (1998). "A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis". N Engl J Med. 338 (7): 409–416. doi:10.1056/NEJM199802123380701. PMID 9459643.
- ↑ Mismetti P, Laporte S, Pellerin O, et al. (2015). "Effect of a Retrievable Inferior Vena Cava Filter Plus Anticoagulation vs Anticoagulation Alone on Risk of Recurrent Pulmonary Embolism: A Randomized Clinical Trial". JAMA. 313 (16): 1627–1635. doi:10.1001/jama.2015.3780. PMID 25919526.
Related chapters
ACC/AHA Guidelines Inferior vena cava filters
External links
IVC filters - Medical College of Wisconsin
IVC filter - GPnotebook.co.uk
History of Lazar Greenfield and his filter - Invention & Technology